{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:40:27Z","timestamp":1793320827577,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T00:00:00Z","timestamp":1684627200000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000942","name":"Brain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.autrev.2022.103118","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T21:53:39Z","timestamp":1652824419000},"page":"103118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Rare antibody-mediated and seronegative autoimmune encephalitis: An update"],"prefix":"10.1016","volume":"21","author":[{"given":"Nabil","family":"Seery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103118_bb0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneurol.2012.99","article-title":"Neuronal autoantigens\u2014pathogenesis, associated disorders and antibody testing","volume":"8","author":"Lancaster","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0010","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain."},{"key":"10.1016\/j.autrev.2022.103118_bb0015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2022.103118_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3988\/jcn.2016.12.1.1","article-title":"The diagnosis and treatment of autoimmune encephalitis","volume":"12","author":"Lancaster","year":"2016","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0035","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","author":"Abboud","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.autrev.2022.103118_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0045","first-page":"1","article-title":"A systematic review of Gamma-aminobutyric Acid Receptor Type B autoimmunity","volume":"53","author":"McKay","year":"2019","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.autrev.2022.103118_bb0050","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1212\/WNL.0b013e3182a35271","article-title":"GABAB receptor autoantibody frequency in service serologic evaluation","volume":"81","author":"Jeffery","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0055","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.4103\/0366-6999.168989","article-title":"Limbic encephalitis associated with anti-\u03b3-aminobutyric Acid B receptor antibodies: a case series from China","volume":"128","author":"Guan","year":"2015","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.autrev.2022.103118_bb0060","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/brain\/awz094","article-title":"The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies","volume":"142","author":"van Coevorden-Hameete","year":"2019","journal-title":"Brain."},{"key":"10.1016\/j.autrev.2022.103118_bb0065","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies","volume":"81","author":"H\u00f6ftberger","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0070","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0b013e31820e7b8d","article-title":"GABAB receptor antibodies in limbic encephalitis and anti-GAD\u2013associated neurologic disorders","volume":"76","author":"Boronat","year":"2011","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0075","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamaneurol.2013.4786","article-title":"Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of \u03b3-aminobutyric acid type B receptor autoimmunity","volume":"71","author":"Kruer","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2022.103118_bb0080","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1152\/physrev.00036.2003","article-title":"Molecular structure and physiological functions of GABAB receptors","volume":"84","author":"Bettler","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.autrev.2022.103118_bb0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/25354","article-title":"Heterodimerization is required for the formation of a functional GABA(B) receptor","volume":"396","author":"White","year":"1998","journal-title":"Nature."},{"key":"10.1016\/j.autrev.2022.103118_bb0090","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1212\/WNL.0b013e318247cd03","article-title":"GABAB receptors: structure, functions, and clinical implications","volume":"78","author":"Benarroch","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.conb.2007.04.001","article-title":"GABAB receptors: synaptic functions and mechanisms of diversity","volume":"17","author":"Ulrich","year":"2007","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.autrev.2022.103118_bb0100","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.1073\/pnas.1201660109","article-title":"Sushi domains confer distinct trafficking profiles on GABAB receptors","volume":"109","author":"Hannan","year":"2012","journal-title":"PNAS."},{"key":"10.1016\/j.autrev.2022.103118_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature20566","article-title":"Organization and functions of mGlu and GABA B receptor complexes","volume":"540","author":"Pin","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.autrev.2022.103118_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuron.2010.03.012","article-title":"GABAB receptors modulate NMDA receptor calcium signals in dendritic Spines","volume":"66","author":"Chalifoux","year":"2010","journal-title":"Neuron."},{"key":"10.1016\/j.autrev.2022.103118_bb0115","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1523\/JNEUROSCI.5635-03.2004","article-title":"Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice","volume":"24","author":"Gassmann","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.autrev.2022.103118_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg3362","article-title":"Molecular mechanisms of metabotropic GABAB receptor function","volume":"7","author":"Shaye","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.autrev.2022.103118_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0896-6273(01)00345-2","article-title":"Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABAB responses in mice lacking GABAB(1)","volume":"31","author":"Schuler","year":"2001","journal-title":"Neuron."},{"key":"10.1016\/j.autrev.2022.103118_bb0130","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bcp.2004.06.037","article-title":"GABAB receptor alterations as indicators of physiological and pharmacological function","volume":"68","author":"Enna","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.autrev.2022.103118_bb0135","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1126\/science.1321503","article-title":"The role of GABAB receptor activation in absence seizures of lethargic (lh\/lh) mice","volume":"257","author":"Hosford","year":"1992","journal-title":"Science."},{"key":"10.1016\/j.autrev.2022.103118_bb0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s002130050632","article-title":"The modulatory effects of high affinity GABA(B) receptor antagonists in an active avoidance learning paradigm in rats","volume":"137","author":"Getova","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.autrev.2022.103118_bb0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/(SICI)1098-1063(1998)8:2<109::AID-HIPO2>3.0.CO;2-G","article-title":"Baclofen infused in rat hippocampal formation impairs spatial learning","volume":"8","author":"Arolfo","year":"1998","journal-title":"Hippocampus."},{"key":"10.1016\/j.autrev.2022.103118_bb0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0006-8993(94)91811-2","article-title":"Stimulation of GABAB receptors in thebasal forebrain selectively impairs working memory of rats in the double Y-maze","volume":"641","author":"DeSousa","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.autrev.2022.103118_bb0155","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bcp.2004.06.037","article-title":"GABAB receptor alterations as indicators of physiological and pharmacological function","volume":"68","author":"Enna","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.autrev.2022.103118_bb0160","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.neuron.2006.04.014","article-title":"Differential compartmentalization and distinct functions of GABAB receptor variants","volume":"50","author":"Vigot","year":"2006","journal-title":"Neuron."},{"key":"10.1016\/j.autrev.2022.103118_bb0165","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1212\/01.WNL.0000046520.79877.D8","article-title":"GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy","volume":"60","author":"Gambardella","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0170","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1523\/JNEUROSCI.3320-13.2013","article-title":"Postsynaptic GABAB receptor activity regulates excitatory neuronal architecture and spatial memory","volume":"34","author":"Terunuma","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.autrev.2022.103118_bb0175","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/jnnp-2014-308814","article-title":"Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series","volume":"86","author":"Dogan Onugoren","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.autrev.2022.103118_bb0180","volume":"78","author":"140th Annual Meeting American Neurological Association","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0185","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/epi4.12067","article-title":"Pathogenic potential of antibodies to the GABAB receptor","volume":"2","author":"Nibber","year":"2017","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.autrev.2022.103118_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000232","article-title":"Evidence of a pathogenic role for CD8(+) T cells in anti-GABAB receptor limbic encephalitis","volume":"3","author":"Golombeck","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0195","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00415-018-9132-0","article-title":"Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis","volume":"266","author":"Maureille","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0200","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/01616412.2017.1351062","article-title":"Encephalitis with antibodies against the GABAB receptor: seizures as the most common presentation at admission","volume":"39","author":"Chen","year":"2017","journal-title":"Neurol. Res."},{"key":"10.1016\/j.autrev.2022.103118_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577471","article-title":"Long-term cognitive and neuropsychiatric outcomes of anti-GABABR encephalitis patients: a prospective study","volume":"351","author":"Lin","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.autrev.2022.103118_bb0210","doi-asserted-by":"crossref","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0215","first-page":"99","article-title":"A Retrospective study of patients with GABABR encephalitis: therapy","volume":"17","author":"Wen","year":"2021","journal-title":"Dis. Activity Prognostic Factors, NDT."},{"key":"10.1016\/j.autrev.2022.103118_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01030","article-title":"Encephalitis with antibodies against the GABAB receptor: high mortality and risk factors","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0225","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000039","article-title":"Autoimmune encephalitis with GABAB antibodies, thymoma, and GABAB receptor thymic expression","volume":"1","author":"Alexopoulos","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jneuroim.2013.04.004","article-title":"GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis","volume":"259","author":"Mundiyanapurath","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.autrev.2022.103118_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00804","article-title":"Cerebrospinal fluid findings in patients with autoimmune encephalitis\u2014a systematic analysis","volume":"10","author":"Blinder","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2014.02.011","article-title":"Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis","volume":"270","author":"Kim","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.autrev.2022.103118_bb0245","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015706","article-title":"Autoimmune encephalitis with anti-IgLON5 and anti-GABAB-receptor antibodies: a case report","volume":"98","author":"Chung","year":"2019","journal-title":"Medicine."},{"key":"10.1016\/j.autrev.2022.103118_bb0250","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103118_bb0255","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00415-018-9153-8","article-title":"Patient characteristics and outcome associations in AMPA receptor encephalitis","volume":"266","author":"Laurido-Soto","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0260","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000682","article-title":"Pediatric autoimmune encephalitis","volume":"7","author":"de Bruijn","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0265","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/acn3.43","article-title":"Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis","volume":"1","author":"Gleichman","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0270","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrn.2016.37","article-title":"Synaptic AMPA receptor composition in development, plasticity and disease","volume":"17","author":"Henley","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.autrev.2022.103118_bb0275","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuron.2018.10.018","article-title":"The AMPA receptor code of synaptic plasticity","volume":"100","author":"Diering","year":"2018","journal-title":"Neuron."},{"key":"10.1016\/j.autrev.2022.103118_bb0280","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.21589","article-title":"AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0285","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.24293","article-title":"Cellular plasticity induced by anti-\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies","volume":"77","author":"Peng","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuron.2018.07.048","article-title":"Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction","volume":"100","author":"Haselmann","year":"2018","journal-title":"Neuron."},{"key":"10.1016\/j.autrev.2022.103118_bb0295","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001019","article-title":"Autoimmune global amnesia as manifestation of AMPAR encephalitis and neuropathologic findings","volume":"8","author":"Ricken","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0300","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1212\/WNL.0000000000001682","article-title":"Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients","volume":"84","author":"H\u00f6ftberger","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0305","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamaneurol.2015.1715","article-title":"Clinical spectrum of encephalitis associated with antibodies against the \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature","volume":"72","author":"Joubert","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0310","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jneuroim.2013.05.011","article-title":"Rapid progression and brain atrophy in anti-AMPA receptor encephalitis","volume":"261","author":"Wei","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.autrev.2022.103118_bb0315","article-title":"Recurrent anti-AMPA receptor encephalitis associated with thymus cancer","author":"Qiao","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.autrev.2022.103118_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1540","article-title":"Different FDG-PET metabolic patterns of anti-AMPAR and anti-NMDAR encephalitis: case report and literature review","volume":"10","author":"Wei","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.autrev.2022.103118_bb0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jneuroim.2014.04.002","article-title":"Serial brain 18FDG-PET in anti-AMPA receptor limbic encephalitis","volume":"271","author":"Spatola","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.autrev.2022.103118_bb0330","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaneurol.2016.1585","article-title":"Characterization of a subtype of autoimmune encephalitis with anti\u2013contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures","volume":"73","author":"Joubert","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0335","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/WCO.0000000000000814","article-title":"Anti-gamma-aminobutyric acid receptor type A encephalitis: a review","volume":"33","author":"Guo","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0340","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature13293","article-title":"Crystal structure of a human GABAA receptor","volume":"512","author":"Miller","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.autrev.2022.103118_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-019-0413-7","article-title":"Human brain transcriptome analysis finds region- and subject-specific expression signatures of GABA A R subunits","volume":"2","author":"Sequeira","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.autrev.2022.103118_bb0350","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1113\/jphysiol.2010.186999","article-title":"Mutations in GABAA receptor subunits associated with genetic epilepsies","volume":"588","author":"Macdonald","year":"2010","journal-title":"J. Physiol."},{"key":"10.1016\/j.autrev.2022.103118_bb0355","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1523\/JNEUROSCI.4415-13.2014","article-title":"Identification and characterization of GABAA receptor autoantibodies in autoimmune encephalitis","volume":"34","author":"Ohkawa","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.autrev.2022.103118_bb0360","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0365","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1916337118","article-title":"Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis","volume":"118","author":"Br\u00e4ndle","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.autrev.2022.103118_bb0370","doi-asserted-by":"crossref","unstructured":"J. Kreye, S.K. Wright, A. van Casteren, L. St\u00f6ffler, M.-L. Machule, S.M. Reincke, M. Nikolaus, S. van Hoof, E. Sanchez-Sendin, M.A. Homeyer, C. Cordero G\u00f3mez, H.-C. Kornau, D. Schmitz, A.M. Kaindl, P. Boehm-Sturm, S. Mueller, M.A. Wilson, M.A. Upadhya, D.R. Dhangar, S. Greenhill, G. Woodhall, P. Turko, I. Vida, C.C. Garner, J. Wickel, C. Geis, Y. Fukata, M. Fukata, H. Pr\u00fcss, Encephalitis patient-derived monoclonal GABAA receptor antibodies cause epileptic seizures, J. Exp. Med. 218 (2021) e20210012. doi:https:\/\/doi.org\/10.1084\/jem.20210012.","DOI":"10.1101\/2021.01.28.428602"},{"key":"10.1016\/j.autrev.2022.103118_bb0375","article-title":"GABAA receptor autoimmunity: A multicenter experience","volume":"6","author":"O\u2019Connor","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/acn3.50974","article-title":"An expanded parenchymal CD8+ T cell clone in GABAA receptor encephalitis","volume":"7","author":"Bracher","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0385","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0390","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/WNL.0000000000001326","article-title":"Antibodies to GABAA receptor \u03b11 and \u03b32 subunits: clinical and serologic characterization","volume":"84","author":"Pettingill","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0395","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000554","article-title":"Encephalitis, severe seizures, and multifocal brain lesions: recognizing autoimmunity to the GABAA receptor","volume":"6","author":"Lancaster","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577114","article-title":"Anti-dipeptidyl-peptidase-like protein 6 encephalitis, a rare cause of reversible rapid progressive dementia and insomnia","volume":"339","author":"Zhou","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.autrev.2022.103118_bb0405","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1212\/WNL.0000000000003796","article-title":"DPPX antibody-associated encephalitis: Main syndrome and antibody effects","volume":"88","author":"Hara","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0410","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0415","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.mcn.2004.06.011","article-title":"Molecular physiology and modulation of somatodendritic A-type potassium channels","volume":"27","author":"Jerng","year":"2004","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.autrev.2022.103118_bb0420","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.neuron.2011.08.008","article-title":"DPP6 establishes the A-type K+ current gradient critical for the regulation of dendritic excitability in CA1 hippocampal neurons","volume":"71","author":"Sun","year":"2011","journal-title":"Neuron."},{"key":"10.1016\/j.autrev.2022.103118_bb0425","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0896-6273(02)01185-6","article-title":"The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels","volume":"37","author":"Nadal","year":"2003","journal-title":"Neuron."},{"key":"10.1016\/j.autrev.2022.103118_bb0430","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1523\/JNEUROSCI.4767-08.2009","article-title":"The dipeptidyl-peptidase-like protein DPP6 determines the unitary conductance of neuronal Kv4.2 channels","volume":"29","author":"Kaulin","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.autrev.2022.103118_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/neuro.02.008.2008","article-title":"DPP6 localization in brain supports function as a Kv4 channel associated protein","volume":"1","author":"Clark","year":"2008","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.autrev.2022.103118_bb0440","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/WNL.0000000000000991","article-title":"DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0445","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000001907","article-title":"Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons","volume":"85","author":"Piepgras","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0450","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1212\/WNL.0000000000001183","article-title":"Neuropathologic features of anti-dipeptidyl-peptidase-like protein-6 antibody encephalitis","volume":"84","author":"Stokin","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0455","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1212\/WNL.0000000000000372","article-title":"Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies","volume":"82","author":"Balint","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0460","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007463","article-title":"Teaching video neuroimages: opsoclonus in anti-DPPX encephalitis","volume":"92","author":"Micieli","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0465","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.5154","article-title":"DPPX autoimmune encephalitis presenting with chronic diarrhea, multidirectional nystagmus, opsoclonus and prominent hyperekplexia (5154)","volume":"94","author":"Arca","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0470","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000455","article-title":"Pruritus in anti-DPPX encephalitis","volume":"5","author":"Wijntjes","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0475","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0480","first-page":"awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","author":"Gr\u00fcter","year":"2022","journal-title":"Brain."},{"key":"10.1016\/j.autrev.2022.103118_bb0485","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0490","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0495","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.autrev.2022.103118_bb0500","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological criteria of anti-IgLON5-related tauopathy","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.autrev.2022.103118_bb0505","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0510","doi-asserted-by":"crossref","first-page":"e1367","DOI":"10.1212\/WNL.0000000000012639","article-title":"Frequency and characterization of movement disorders in anti-IgLON5 disease","volume":"97","author":"Gaig","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0515","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3389\/fneur.2019.01056","article-title":"Anti-IgLON5 disease: a case with 11-year clinical course and review of the literature","volume":"10","author":"Nissen","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0520","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ane.13207","article-title":"Response to immunotherapy in anti-IgLON5 disease: a systematic review","volume":"141","author":"Cabezudo-Garc\u00eda","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.autrev.2022.103118_bb0525","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s00415-020-09924-y","article-title":"Early immunotherapy is highly effective in IgG1\/IgG4 positive IgLON5 disease","volume":"267","author":"Gr\u00fcter","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0530","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000592","article-title":"Novel clinical features of glycine receptor antibody syndrome","volume":"6","author":"Piquet","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0535","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/ene.13721","article-title":"Antiglycine receptor antibody related disease: a case series and literature review","volume":"25","author":"Swayne","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0540","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonz\u00e1lez","year":"2014","journal-title":"Brain."},{"key":"10.1016\/j.autrev.2022.103118_bb0545","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamaneurol.2016.0133","article-title":"Clinical and immunologic investigations in patients with stiff-person spectrum disorder","volume":"73","author":"Martinez-Hernandez","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0550","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mGluR5 antibodies: Symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0555","doi-asserted-by":"crossref","first-page":"e3012","DOI":"10.1212\/WNL.0000000000010854","article-title":"Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis","volume":"95","author":"Spatola","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0560","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000658","article-title":"Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2","volume":"7","author":"Ruiz-Garc\u00eda","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0565","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1212\/WNL.0000000000006035","article-title":"Glutamate receptor \u03b42 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome","volume":"91","author":"Berridge","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0570","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1212\/WNL.0000000000002775","article-title":"Human neurexin-3\u03b1 antibodies associate with encephalitis and alter synapse development","volume":"86","author":"Gresa-Arribas","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.autrev.2022.103118_bb0575","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/brain\/aws256","article-title":"Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders","volume":"135","author":"Dale","year":"2012","journal-title":"Brain."},{"key":"10.1016\/j.autrev.2022.103118_bb0580","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/jamaneurol.2013.1955","article-title":"Patient with homer-3 antibodies and cerebellitis","volume":"70","author":"H\u00f6ftberger","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.837937","article-title":"Acute cerebellitis associated with anti-homer 3 antibodies: a rare case report and literature review","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0590","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ana.26017","article-title":"CaV \u03b12\u03b4 autoimmune encephalitis: a novel antibody and its characteristics","volume":"89","author":"Lee","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0595","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ana.26098","article-title":"GluK2 encephalitis study group, encephalitis with autoantibodies against the Glutamate Kainate receptors GluK2","volume":"90","author":"Landa","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0600","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/WNN.0b013e31828b6531","article-title":"Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review, Cogn","volume":"26","author":"Najjar","year":"2013","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0605","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1136\/jnnp-2019-anzan.65","article-title":"077 An unusual presentation of antibody negative autoimmune encephalitis: a case report","volume":"90","author":"Upadhyay","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.autrev.2022.103118_bb0610","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2018.06.021","article-title":"Electroclinical features of seizures associated with autoimmune encephalitis","volume":"60","author":"Steriade","year":"2018","journal-title":"Seizure."},{"key":"10.1016\/j.autrev.2022.103118_bb0615","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/ene.13661","article-title":"Syndrome and outcome of antibody-negative limbic encephalitis","volume":"25","author":"Graus","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0620","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.23917","article-title":"A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma","volume":"75","author":"Armangue","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0625","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/WNN.0000000000000134","article-title":"Seronegative Paraneoplastic Limbic Encephalitis Associated with Thymoma, Cogn","volume":"30","author":"Toro","year":"2017","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0630","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/practneurol-2011-000084","article-title":"Seronegative limbic encephalitis: case report, literature review and proposed treatment algorithm","volume":"11","author":"Ahmad","year":"2011","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0635","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13256-021-02742-4","article-title":"Seronegative limbic encephalitis manifesting as subacute amnestic syndrome: a case report and review of the literature","volume":"15","author":"Ismail","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.autrev.2022.103118_bb0640","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000352","article-title":"Abnormal brain metabolism on FDG-PET\/CT is a common early finding in autoimmune encephalitis","volume":"4","author":"Probasco","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.autrev.2022.103118_bb0645","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3988\/jcn.2021.17.2.300","article-title":"Clinical Features and Treatment Outcomes of Seronegative Pediatric Autoimmune Encephalitis","volume":"17","author":"Lee","year":"2021","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.autrev.2022.103118_bb0650","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rpsm.2019.10.002","article-title":"Psychosis as an initial symptom of autoimmune encephalitis with negative antibodies","volume":"14","author":"Pe\u00f1a-Salazar","year":"2021","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)."},{"key":"10.1016\/j.autrev.2022.103118_bb0655","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imj.7_13579","article-title":"Cgr 7: Early empirical treatment of antibody-negative autoimmune\/paraneoplastic encephalitis with immunosuppression","volume":"47","author":"Dai","year":"2017","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.autrev.2022.103118_bb0660","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/brain\/awz297","article-title":"Glycine receptor autoantibodies disrupt inhibitory neurotransmission","volume":"142","author":"Crisp","year":"2019","journal-title":"Brain."},{"key":"10.1016\/j.autrev.2022.103118_bb0665","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ana.25832","article-title":"Glycine receptor autoantibodies impair receptor function and induce motor dysfunction","volume":"88","author":"Rauschenberger","year":"2020","journal-title":"Ann. Neurol."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722200088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722200088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:25:14Z","timestamp":1761600314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722200088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":133,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S156899722200088X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103118","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rare antibody-mediated and seronegative autoimmune encephalitis: An update","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103118"}}